统计剂使用与脑下出血风险之间的关联:使用大规模索赔数据的案例对照研究
Makoto Hagiwara1, Ayako Maeda-Minami1, Fumihiro Matano2
1Faculty of Pharmaceutical Sciences, Tokyo University of Science, Japan (M.H., A.M.-M., Y. Mano).
立方体使用与下arachnoid出血 (SAH) 的风险较低有关. 这表明他类药物可能有助于预防SAH,特别是患有高血压或脑血管疾病的患者.
科学领域:
- 神经学 神经学
- 心血管医学 心血管医学
- 药理学 药理学是指药理学的学科.
背景情况:
- 副arachnoid出血 (SAH) 的风险和他类药物的有效性仍然不清楚.
- 类药物是降胆固醇剂,具有潜在的神经保护作用.
研究的目的:
- 调查他类药物使用与子arachnoid出血 (SAH) 风险之间的关联.
- 探索这种关联是否受到先前存在的条件的改变.
主要方法:
- 使用日本医疗保险索赔数据库 (2005-2021) 进行的一项大型基于人口的病例控制研究.
- 分析了3498个SAH病例和13992个匹配的对照.
- 条件后勤回归调整为共变量评估的他类药物暴露和SAH风险.
主要成果:
- 斯坦丁使用与SAH风险显著降低有关 (aOR 0.81;95% CI,0.69-0.95).
- 这种关联在很大程度上受高血压或脑血管疾病史的影响.
结论:
- 达丁类药物使用与SAH风险降低显著相关.
- 类药物可能在SAH预防中起到保护作用,特别是在高血压或脑血管疾病患者中.
更多相关视频
09:14Pre-Chiasmatic, Single Injection of Autologous Blood to Induce Experimental Subarachnoid Hemorrhage in a Rat Model
Published on: June 18, 2021
06:55Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
Published on: January 8, 2020
相关概念视频
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Atherosclerosis III: Management
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Genome-wide Association Studies-GWAS
GWAS does not require the identification of the target gene involved in...
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
